La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 4D Molecular Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 4D Molecular Therapeutics..

4D Molecular Therapeutics (NASDAQ:FDMT) Azioni, Catena delle Opzioni

4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics Inc

Food safety solutions provider Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Monday</a> after selling its Cleaners &amp; Disinfectants Business.
The company has finalized an agreement to divest its worldwide cleaners and disinfectants division to Kersia Group, a leading company in hygiene and biosecurity solutions, in a cash transaction valued at $130 million.
The agreement includes additional contingent payments based on the business's future performance. The transaction, subject to regulatory approval, is expected to conclude in the first quarter of FY26.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44895043/target-rolls-out-standalone-flower-brand-good-little-garden" rel="noreferrer noopener">Target Rolls Out Standalone Flower Brand ‘Good Little Garden'</a>
"The sale of our cleaners and disinfectants business further focuses Neogen on food safety diagnostics and continuing to build on our leadership position in what we believe is an attractive end market with long-term tailwinds," said President and CEO of Neogen, John Adent.
"We expect Kersia's prioritization of investment and growth in the biosecurity market will benefit the business and provide sharpened strategic focus to maximize its potential for continued growth."
Proceeds from the sale will enable Neogen to eliminate its $100 million revolving credit debt, following a recent refinancing move.
The company expects the transaction to improve profit margins and lower its net leverage ratio by roughly 0.4x on a pro forma basis.
Neogen's disinfectant and cleaning product line, which brings in about $60 million in yearly revenue, supports various livestock markets such as poultry, swine, and ruminants.
Price Action: NEOG shares traded higher by 7.14% at $4.71 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44897010/chipotle-to-open-first-mexico-restaurant-by-2026" target="_blank" rel="noreferrer noopener">Chipotle To Open First Mexico Restaurant By 2026</a></li>
</ul>

News

Asset Sales

General

NEOG

Testing Firm Neogen Offloads Cleaners Division To Kersia In $130 Million Deal

Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are trading lower by 2.2% to $36.60 during Monday&#8217;s session amid overall market weakness. The company last week reported first-quarter fiscal 2025 results, with results that <a href="https://www.benzinga.com/news/earnings/25/04/44811593/bank-of-america-ceo-says-consumer-continues-to-spend-and-maintain-healthy-credit-quality-sticks-to-annual-outlook">topped Wall Street expectations</a>. 
The bank posted net income of $7.4 billion, up from $6.7 billion a year earlier, with earnings per share of 90 cents, beating the consensus estimate of 81 cents. Revenue rose 6% to $27.37 billion, driven by growth in both noninterest and net interest income.
Bank of America's Consumer and Global Banking divisions posted slight profit declines, while Global Markets and Wealth Management showed gains. Credit loss provisions rose 12% to $1.48 billion. The CET1 capital ratio slipped to 11.8%, though book value per share rose 8% to $36.39.
CEO Brian Moynihan emphasized consumer resilience and reaffirmed the bank's long-term strategy, but analysts noted rising macro risks and revised down forecasts, potentially contributing to the stock's decline despite the otherwise strong quarter.
Read Also: <a href="https://www.benzinga.com/25/04/44896337/teslas-q1-test-drive-will-earnings-steer-tesla-stock-out-of-the-ditch">Tesla Q1 Test Drive: Will Earnings Steer The Stock Out Of The Ditch?</a>
What Else: However, investor sentiment has been soured after Federal Reserve Chair Jerome Powell last week <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44848474/fed-chair-powell-says-tariffs-lead-to-temporary-rise-in-inflation">warned of heightened inflation risks</a> and weakening growth tied to new U.S. trade tariffs. Powell's remarks Wednesday pointed to &#8220;notable deterioration&#8221; in consumer and business sentiment, adding uncertainty to the macro outlook.
The <a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">dollar sank Monday</a> amid fears President&nbsp;Donald Trump&nbsp;could move to oust Federal Reserve Chair&nbsp;Jerome Powell&nbsp;before his term expires in May 2026.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">Dollar Hits 3-Year Lows, US Stocks Tumble As Trump Threatens To Fire Powell: &#8216;Contrarians Of The World, Unite!&#8217;</a>
Investors can gain exposure to&nbsp;BAC by&nbsp;investing&nbsp;in the Financial Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NASDAQ">XLF</a>).
<h2 class="wp-block-heading">How To Buy BAC Stock</h2>
By now you're likely curious about how to participate in the market for Bank of America &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Bank of America, which is trading at $36.64 as of publishing time, $100 would buy you 2.73 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BAC has a 52-week high of $48.08 and a 52-week low of $36.60.

What's Going On With Bank Of America (BAC) Shares?

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) are trading lower Monday amid broader market weakness following cautious comments from Federal Reserve Chair Jerome Powell <a href="https://www.benzinga.com/25/04/44866378/whats-going-on-with-palantir-stock-today">last week</a> and President Donald Trump&#8216;s <a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">criticism of Powell.</a>
What To Know: On Wednesday, Powell warned that tariffs could push inflation higher and said the economy is showing signs of slowing, which spooked investors and raised concerns about future federal and commercial spending—key revenue sources for Palantir.
This drop comes despite several major developments for the company over the past month. Palantir was named in reports linking it to President Trump's proposed missile defense system, the "Golden Dome," alongside SpaceX and defense firm Anduril. Around the same time, the company announced a new partnership with Anthropic to bring its Claude AI model to U.S. government agencies through Palantir's FedStart platform.
Palantir also closed a fast-tracked <a href="https://www.benzinga.com/content/44836938/nato-deal-sparks-4-jump-in-palantir-stock-whats-next">deal with NATO</a> for its Maven Smart System NATO (MSS NATO), a military AI platform designed to support intelligence and battlefield operations. The deal went from concept to signed contract in six months, a fast timeline for NATO procurement.
Despite these wins, Morgan Stanley cut its price target on Palantir from $95 to $90 while maintaining an Equal-Weight rating. The stock is still up over 300% in the past year but is now reacting more to macroeconomic risks than individual contract wins.
The stock remains technically strong in some areas, trading above its 20- and 200-day moving averages, but it dipped below its 50-day average and is showing mixed momentum signals. 
PLTR Price Action: Palantir shares were down 4.52% at $89.54 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51-1024x532.png" alt="" class="wp-image-880396" style="width:422px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51-1536x798.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21140909/Screenshot-2025-04-21-at-14.08.51.png 1541w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44904179/wall-street-sinks-dollar-slides-as-trump-ramps-up-fed-attacks-whats-driving-markets-monday">Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

Movers

PLTR

Palantir Stock Tumbles As Broader Tech Weakens: What's Going On?

Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) on Monday released topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy&nbsp;(sacituzumab govitecan-hziy) plus Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) <a href="https://www.benzinga.com/general/health-care">Keytruda&nbsp;(pembrolizumab)</a>.
The trial demonstrated that Trodelvy plus Keytruda&nbsp;significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44895548/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvem" rel="noreferrer noopener">PD-L1 (CPS ≥ 10)</a>.
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44395415/trump-administration-weighs-deep-cuts-to-domestic-hiv-prevention-programs-gilead-stock-slides" target="_blank" rel="noreferrer noopener">Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides</a>
The safety profile of Trodelvy plus Keytruda in the ASCENT-04 study was consistent with each agent&#8217;s known safety profile. No new safety signals were identified with the combination.
&#8220;These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,&#8221; said Dietmar Berger Chief Medical Officer, Gilead Sciences.
Overall survival (OS) is a key secondary endpoint and was not mature at the time of the PFS primary analysis. However, in the ASCENT-04 study, there was an early trend in improvement for OS with Trodelvy plus Keytruda.
Gilead will continue to monitor OS outcomes, with ongoing patient follow-up and further analyses planned.
Detailed results from the study will be presented at a future medical meeting and discussed with regulatory authorities.
The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established.
Trodelvy is the only approved Trop-2-directed antibody-drug conjugate (ADC) that has demonstrated meaningful survival advantages in two types of metastatic breast cancers: 2L+ mTNBC and pre-treated HR+/HER2- mBC.
It is a Category 1 preferred treatment for both indications per the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the only ADC with an ESMO Magnitude of Clinical Benefit Scale (MCBS) rating of 5 for mTNBC.
Trodelvy also has an MCBS rating of 4 for women with HR+/HER2- mBC.
Currently, Gilead has three ongoing Phase 3 studies investigating Trodelvy across HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) mBC, including the upcoming ASCENT-03 pivotal trial in 1L mTNBC patients who are not candidates for PD-L1 based therapy, the ASCENT-05 pivotal trial in patients with early-stage TNBC, and the ASCENT-07 pivotal trial in patients with HR+/HER2- mBC who have received endocrine therapy.
Trodelvy is also being investigated in additional Phase 3 studies in other disease settings, including lung and gynecological cancers.
Price Action: GILD stock is down 0.46% at $104.06 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44902345/upexi-raises-100-million-to-expand-crypto-ventures-stock-soars" target="_blank" rel="noreferrer noopener">Upexi Raises $100 Million To Expand Crypto Ventures, Stock Soars</a></li>
</ul>
Photo by Michael Moloney via Shutterstock

Biotech

Large Cap

Health Care

GILD

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1024" height="608" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21174035/image-13.png" alt="" class="wp-image-11210" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21174035/image-13.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21174035/image-13-300x178.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/21174035/image-13-768x456.png 768w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The image is AI-generated
Earnings estimates for the next 12 months are rising.
And earnings estimates for 2025 and 2026 have been coming down.
The above statements sound like they're in conflict. But they are actually two&nbsp;<a href="https://substack.com/redirect/0b428c4f-94a3-4eca-867a-9071583c8777?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">ways of communicating</a>&nbsp;the&nbsp;<a href="https://substack.com/redirect/a5308509-c43c-4f32-bf7f-4cbaa8184f4e?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">same information</a>. The differentiating factor: The passage of time.
Calendar year vs. NTM earnings estimates&nbsp;
We often hear analysts talk about earnings estimates based on&nbsp;calendar years. For example, coming into this year Wall Street strategists presented their&nbsp;<a href="https://substack.com/redirect/d2fcbbd5-785d-44cf-89cb-778917cbbd04?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">estimates for 2025 earnings</a>.
As time passes and information emerges,&nbsp;<a href="https://substack.com/redirect/22f4dde1-df4a-49a9-86c4-a3295477d6df?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">analysts will adjust those estimates</a>. Historically,&nbsp;<a href="https://substack.com/redirect/0188d832-2a15-4595-90b0-d82599b8c1ad?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">analysts tend</a>&nbsp;to gradually&nbsp;<a href="https://substack.com/redirect/48d4d293-0e8e-4b9c-8595-53393df0b0a3?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">revise down</a>&nbsp;these calendar year estimates. And so far,&nbsp;<a href="https://substack.com/redirect/82be0da4-a482-4567-94fd-a70e689559d6?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">this has been the case in 2025</a>.
However,&nbsp;<a href="https://substack.com/redirect/342af7c2-b95c-4bef-97d5-e237a475db0b?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">time can pass quickly</a>. And with calendar year estimates, what was once a discussion about future earnings can quickly become a discussion about past earnings.
For example, at the beginning of the year, 2025 earnings represented the next-12 months' (NTM) earnings. But it's April now, which means any discussion of 2025 earnings involves an old quarter, and any discussion of&nbsp;<a href="https://substack.com/redirect/8a401c08-d6f9-4731-8f55-3d98263a93bd?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">NTM earnings</a>&nbsp;involves a quarter in 2026.
Morgan Stanley's Michael Wilson shared a nice side-by-side visualization of this somewhat confusing dynamic. The chart on the left shows the S&amp;P 500's NTM earnings per share (EPS). As time passes, you can see NTM EPS move up as it continuously incorporates the higher earnings expected in future periods.
The chart on the right shows EPS estimates for 2025 and 2026 — static periods in time. As time passes, you can see how analysts' estimates have moved lower in recent months.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td></td>
<td><img loading="lazy" decoding="async" width="550" height="187" src="blob:https://contributor.benzinga.com/893e7645-3b3f-4da5-9f17-b06149334f44" /><a href="https://substack.com/redirect/efad4a0a-c4db-49a0-8c59-14336728409f?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener"></a></td>
<td></td>
</tr>
</tbody>
</table>
</figure>
NTM earnings estimates look good despite calendar year estimates coming down. (Source: Morgan Stanley)
"NTM EPS estimates continue to advance on the back of stronger 2026 EPS growth," Wilson observed. "However, NTM EPS may show signs of flattening in recent weeks as 2025/2026 estimates revise slightly lower (-1%)."
To be clear, both charts employ the same analysts' estimates for earnings. They just differ in the way they reflect the effect of the passage of time.
And the two charts are currently telling us that the promise of earnings growth on a rolling future basis is more than offsetting deteriorating expectations for static periods.
This is important&nbsp;<a href="https://substack.com/redirect/342af7c2-b95c-4bef-97d5-e237a475db0b?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">in the context of valuation metrics</a>&nbsp;like the&nbsp;<a href="https://substack.com/redirect/03d88312-205c-4fe0-bd16-37890cbc0883?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">forward price-earnings (P/E) ratio</a>. If earnings are expected to grow, then forward earnings (E) will rise as time passes. This leads to downward pressure on P/E ratios.
Be mindful in this uncertain environment&nbsp;
As&nbsp;<a href="https://substack.com/redirect/379e1d53-9bdd-4f7c-ac3f-c8c272798793?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">we discussed last week</a>, there are currently a lot of issues with analysts' earnings estimates.&nbsp;<a href="https://substack.com/redirect/99def433-1d70-418f-862d-84d02780ab03?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">Uncertainty is very high</a>, and there&#8217;s evidence that the&nbsp;<a href="https://substack.com/redirect/10ab8cb9-cce7-4aae-8f16-a8168741bcf3?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">earnings estimates</a>&nbsp;out there right now&nbsp;<a href="https://substack.com/redirect/379e1d53-9bdd-4f7c-ac3f-c8c272798793?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">are stale</a>.
But again, both visualizations are working off the same estimates. So if we believe the estimates for E is off, discussions about both NTM and calendar year estimates will similarly be off.
The bottom line: Be mindful about what you read and hear about earnings estimates. While it can be helpful to know what's going on with revisions in certain calendar years, the information for a particular year will become less relevant as time passes. This is why it's arguably more useful to look to NTM earnings because stock prices are&nbsp;<a href="https://substack.com/redirect/b700d46e-4ff3-40fa-997e-e505338cd526?j=eyJ1IjoiNThoaTNqIn0.oQOskqZ_hj7KyeETRBdER4rAvQcgl0VTn-sq5tqKUD0" target="_blank" rel="noreferrer noopener">heavily determined by expectations for the future</a>.

Earnings

Equities

Opinion

Markets

Trading Ideas

Making Sense Of Seemingly Conflicting Statements About Earnings Estimates

APVO

Aptevo Therapeutics Shares Resume Trading

Aptevo Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Up 4.42%

JPMorgan analyst Andrew C. Steinerman slashed the price forecast of ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) following its first-quarter <a href="https://www.benzinga.com/25/04/44864777/why-staffing-firm-manpowers-stocks-are-plunging-on-thursday" target="_blank" rel="noreferrer noopener">fiscal year 2025 results reported last week</a>.
The company reported a sales decline of 7.1% year-on-year to $4.09 billion, beating the analyst consensus estimate of $3.96 billion, and adjusted EPS was 44 cents, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">missing the consensus of 50 cents</a>.
ManpowerGroup expects second-quarter EPS of 65 cents to 75 cents, <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus an estimate of 95 cents</a>.
Steinerman cut the price forecast from $65 to $50 while<a target="_blank" href="https://www.benzinga.com/quote/MAN/analyst-ratings" rel="noreferrer noopener"> retaining a Neutral rating.</a>
The analyst notes that higher SG&amp;A expenses contributed to the EPS miss, owing to ongoing investments in the back-office transformation efforts.
The analyst acknowledges the company&#8217;s decision to provide second-quarter guidance amid the highly uncertain environment, a step many companies might avoid.
However, concerns around tariffs go well beyond the near term, and the market&#8217;s negative response likely reflects unease over the limited visibility into potential longer-term impacts, adds the analyst.
The analyst says that management caveated their cautious outlook by highlighting potential upsides from a resolution in U.S.-European trade tensions, which could boost staffing demand.
Additionally, Manpower's view that ongoing trade disputes may drive greater economic self-sufficiency in Europe, notes the analyst.
Steinerman lowered adjusted EPS estimates for FY25 to $3.01 (from $4.03) and for FY26 to $5.33 (from $6.45).
Investors can gain exposure to the stock via WisdomTree U.S. SmallCap Quality Dividend Growth Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGRS#NASDAQ">DGRS</a>).
Price Action: ManpoweGroup shares are down 0.97% at $39.72 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44890509/these-large-cap-tech-and-healthcare-stocks-had-a-poor-run-in-easter-week-apr-14-apr-18-are-these-in-your-portfolio" target="_blank" rel="noreferrer noopener">These Large Cap Tech And Healthcare Stocks Had A Poor Run In Easter Week (Apr 14-Apr 18): Are These In Your Portfolio?</a></li>
</ul>
Image: Shutterstock

Price Target

DGRS

ManpowerGroup Must Beware Of Tariff Overhang Despite EU Upside: JPMorgan

SEATTLE, WASHINGTON / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 21, 2025 / Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR&#x2122; and ADAPTIR-FLEX&#x2122; platform technologies, announced today that it has entered into definitive securities purchase agreements for the purchase and sale of 2,324,000 shares of the Company's common stock in a registered direct offering (the "offering") at a purchase price of $0.862 per share. The offering is expected to close on or about April 22, 2025 subject to the satisfaction of customary closing conditions.
Aptevo expects the gross proceeds from the offering to be approximately $2.0 million, before deducting the placement agent's fees and other estimated offering expenses payable by the Company. Aptevo intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes.
 &nbsp;
 &nbsp;

Aptevo Therapeutics Enters Into Definitive Securities Purchase Agreements For Purchase And Sale Of 2.32M Shares In Registered Direct Offering At $0.862/Shr

Macro Economic Events

WIIM

Economics

Gold is trading higher amid a drop in the US dollar.

J.P. Morgan says Perrigo Company plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) first-quarter 2025 earnings will be dominated by commentary on the potential impact of tariffs. The analyst says, &#8220;Tariffs could potentially have a significant impact on PRGO&#8217;s near-term earnings.&#8221;
Analysts forecast adjusted earnings of 55 cents per share, with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $1.09 billion</a>.
Analyst Chris Schott says tariffs could lead the OTC drugs company to a low to mid-single-digit impact on global COGS on an annualized basis, and that the company expects to offset this impact with supply chain efficiencies and price actions.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/44049396/perrigo-outlines-2025-growth-plans-projects-sales-boost-and-margin-expansion-by-2027" rel="noreferrer noopener">Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027</a>
This mainly affects the oral care business, some of which is sourced from China, and the infant formula business, which uses ingredients from both China and India.
The company originally expected to reduce the impact through supply chain improvements and price increases. However, a few challenges remain:
<ul>
<li><a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">Tariffs on Chinese products</a> have gone up significantly since April 2.</li>
<li>It&#8217;s still unclear how pharmaceutical tariffs will turn out, and any tariff on ingredients could affect Perrigo.</li>
<li>The company&#8217;s price hikes have usually lagged behind rising costs.</li>
<li>Since PRGO operates with lower profit margins than its peers, it&#8217;s harder for them to absorb these extra costs.</li>
</ul>
Schott says it&#8217;s hard to predict the short-term impact on Perrigo&#8217;s business, since higher costs without raising prices could hurt its earnings. However, the company is expected to pass most of those cost increases on to consumers, so any effect on its earnings beyond 2026 should be small.
&#8220;Net-net, while tariffs will clearly impact near-term earnings (which is obviously less than ideal with PRGO just seeing a rebound in earnings following its 1H24 nutritional headwinds), we anticipate the company to be able to largely offset said impact by 2026,&#8221; Schott writes.
Price Action: PRGO stock is down 4.70% at $24.13 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44905908/world-economic-forum-chair-klaus-schwab-resigns-after-55-years-interim-successor-takes-over" target="_blank" rel="noreferrer noopener">World Economic Forum Chair Klaus Schwab Resigns After 55 Years, Interim Successor Takes Over</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Guidance

Analyst Ratings

PRGO

Trump Tariffs Could Have 'Significant Impact' On Perrigo Earnings, Says JP Morgan

COLUMBIA, S.C., April 21, 2025 (GLOBE NEWSWIRE) -- Harsco Rail, a division of Enviri Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRI#NYSE">NVRI</a>), today announced Gary Lada as its new president of Harsco Rail, effective May 5, 2025. Lada will replace Claus Heuschmid, who will leave the organization effective June 1, 2025.
 &nbsp;

NVRI

Enviri Appoints Gary Lada As President of Harsco Rail, Effective May 5, 2025

BofA Securities analyst Sara Senatore provides an analysis for restaurant sector performance in the first <a href="https://trello.com/c/f3PFGoRF/331021-restaurants-q1-previewbofa">quarter</a>.
Restaurant demand showed mixed results due to weather and a calendar shift, said the analyst. 
Black Box industry data revealed a deceleration in same-store sales growth (SSSG) across all segments from January to February, but March saw improvement, excluding Fine Dining. 
Restaurant spending growth improved in March, with chain spending recovering from -7.5% in February to -3.5%.
Independent restaurants saw a rise in spending, from -2.7% in February to +1.3%. The rebound was attributed to better weather and the impact of the calendar shift in February. 
In the first quarter, prices for soybeans, wheat and soybean oil continued to deflate, though at a slower rate than in the fourth quarter of FY24. 
Also Read: <a href="https://www.benzinga.com/news/25/04/44897010/chipotle-to-open-first-mexico-restaurant-by-2026">Chipotle To Open First Mexico Restaurant By 2026</a>
Coffee prices surged, increasing by 96.8% year-over-year, up from 56.8% in the fourth quarter. Beef inflation rose to 5.5%, compared to 1.3% in the previous quarter.
Cheese prices decreased by 1.8%, while dairy inflation slowed to 1.3%. Futures markets predict deflation in several commodities in the second quarter of 2025, but coffee, natural gas and beef are expected to see inflation, noted the analyst.
Restaurants index in the S&amp;P 500 is trading at 1.2x forward EPS, below its 5-year, 10-year and 15-year averages of 1.4x.
Industry data indicates a demand recovery in March after weak months in January and February. While consensus expectations for restaurants remain high, first-quarter results may fall short of estimates. 
Investors are focused on April trends and the potential impact of tariffs on consumer sentiment, traffic and COGS inflation.
So, keeping the above points in mind, the analyst has lowered the price targets for Bloomin&#8217; Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>), Dutch Bros Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>), Cheesecake Factory Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>), Cracker Barrel Old Country Store Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>), Chipotle Mexican Grill Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), Krispy Kreme Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>), Domino&#8217;s Pizza Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), Brinker International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>), Jack In The Box Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>), McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Papa John&#8217;s International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>), Restaurant Brands International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>), Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Sweetgreen Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), Shake Shack Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), Sysco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>), Texas Roadhouse Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>), Wendy&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>), Wingstop Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>), and Yum! Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>).
Read Next: • <a href="https://www.benzinga.com/news/25/04/44895043/target-rolls-out-standalone-flower-brand-good-little-garden">Target Rolls Out Standalone Flower Brand &#8216;Good Little Garden&#8217;</a>
Photo: <a href="https://www.shutterstock.com/g/Rawpixel">Rawpixel.com</a> via Shutterstock

Restaurants

BLMN

BROS

CAKE

CBRL

DNUT

JACK

PZZA

SBUX

SHAK

TXRH

WING

Restaurant Sector Q1 Volatilty From Weather, Inflation — Analyst Lowers Price Targets

<a href="https://www.cnbc.com/2025/04/21/amazon-has-paused-some-data-center-lease-commitments-wells-fargo.html?msockid=21c662101c496b42343370ae1de86aaa">https://www.cnbc.com/2025/04/21/amazon-has-paused-some-data-center-lease-commitments-wells-fargo.html?msockid=21c662101c496b42343370ae1de86aaa</a>

AMZN

'Amazon Has Paused Some Data Center Lease Commitments, Wells Fargo Says'- CNBC

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) on Monday said it will pay $300 million to resolve federal allegations that the company filled millions of invalid prescriptions for opioids <a href="https://www.benzinga.com/topic/opioids">and other controlled substances</a>.
Earlier this year, the U.S. Department of Justice filed a civil complaint against Walgreens and its subsidiaries, alleging widespread violations of the Controlled Substances Act (CSA) and <a href="https://www.benzinga.com/25/01/43104245/justice-department-accuses-walgreens-of-violating-drug-laws-in-opioid-epidemic-ignored-red-flags-in-opioid-crisis" target="_blank" rel="noreferrer noopener">False Claims Act (FCA)</a>.
The settlement, announced by the Justice Department, Drug Enforcement Administration (DEA), and the Department of Health and Human Services Office of Inspector General (HHS-OIG), addresses violations of the Controlled Substances Act and False Claims Act.
An additional $50 million will be <a target="_blank" href="https://www.justice.gov/opa/pr/walgreens-agrees-pay-350m-illegally-filling-unlawful-opioid-prescriptions-and-submitting" rel="noreferrer noopener">owed</a> if Walgreens is sold or merged before fiscal year 2032.
Sycamore Partners agreed to acquire Walgreens for $11.45 per <a href="https://www.benzinga.com/25/03/44377660/walgreens-executive-chair-stefano-pessina-seeks-to-strengthen-control-with-nearly-double-stake" target="_blank" rel="noreferrer noopener">share in March</a>.
Federal authorities alleged that from August 2012 to March 2023, Walgreens knowingly dispensed millions of controlled substance prescriptions that raised serious red flags.
These included excessive opioid quantities, early refills, and combinations known as the "trinity," a high-risk cocktail of drugs often linked to abuse. Despite clear signs these prescriptions lacked legitimate medical purposes, Walgreens pharmacists were allegedly pressured to prioritize speed over due diligence.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44685591/walgreens-boots-alliance-q2-earnings-beats-expectations-suspends-guidance-amid-pending-private-equity-deal-with-sycamore-partners" rel="noreferrer noopener">Walgreens Boots Alliance Q2 Profit Falls 47.5%, Suspends Guidance On Pending Private Equity Deal</a>
According to the complaint, Walgreens&#8217; internal practices further contributed to the misconduct. Compliance officials reportedly failed to act on substantial evidence of unlawful dispensing. The company allegedly withheld critical information from pharmacists, including internal prescriber data, and blocked efforts to warn colleagues about potentially problematic prescribers.
The Justice Department accused Walgreens of creating an environment that discouraged pharmacists from taking necessary steps to ensure valid prescriptions.
Alongside the financial settlement, Walgreens has agreed to implement long-term compliance measures. For example, it will require pharmacists to verify the legitimacy of controlled substance prescriptions. It will also conduct annual training, and ensure staffing levels support legal compliance.
Walgreens must also block prescriptions from prescribers known to issue illegitimate prescriptions.
Separately, Walgreens entered into a five-year Corporate Integrity Agreement with HHS-OIG, which establishes a comprehensive compliance program. The process includes employee training, oversight by the company's board, and regular reporting to HHS-OIG regarding controlled substances.
Following the settlement, the U.S. government moved to dismiss its complaint. Walgreens will seek to dismiss a related declaratory judgment case filed in Texas.
In November, Walgreens agreed to pay $100 million to settle a proposed class action lawsuit over its <a href="https://www.benzinga.com/news/large-cap/24/11/41741814/walgreens-agrees-to-100-million-settlement-over-alleged-deceptive-pricing-of-generic-drugs">Prescription Savings Club</a>.
Price Action: Walgreens stock is down 0.46% at $10.84 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" target="_blank" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a></li>
</ul>
Image: Shutterstock

Legal

Walgreens Must Pay $300 Million In Opioid Case, Additional $50 Million If Sold Or Merged Before 2032

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is scheduled to release its first quarter 2025 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">earnings on 29 April</a>.
Analysts forecast adjusted earnings of 70 cents per share with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44377465/pfizer-invites-public-to-view-and-listen-to-webcast-of-april-29-conference-call-with-analysts" rel="noreferrer noopener">sales of $14.26 billion</a>.
BofA updated its earnings model for 1Q25 as analyst Tim Anderson lowered total revenue estimates by -2.1%, primarily due to updated assumptions regarding the impact of Part D on the portfolio and tweaks to Paxlovid seasonality. EPS follows, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">decreasing by -4.9%</a>.
For 2025 and 2026, BofA increased total revenue estimates slightly (&lt;1%), partly related to updated FX assumptions and smaller product-level revisions. The analyst increased EPS estimates by +1.2% and +5.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Citing a relative pharma group whose P/E multiple has recently declined due to tariff and drug pricing fears, BofA has reduced Pfizer&#8217;s price target from $29 to $26, reiterating its Neutral rating.
Pfizer&#8217;s stock is trading at about 7 times its expected 2024 earnings, which is lower than the peer average of around 11 times (excluding Eli Lilly and Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>)).
It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due to upcoming patent expirations and rising competition for some of its key products.
Anderson says the focus of the earnings call will likely include:
<ul>
<li>A few months into the new administration, there is still uncertainty about how agencies like the Department of Health and Human Services (HHS) and the Centers for Medicare &amp; Medicaid Services (CMS) will operate under new leadership.
<ul>
<li>This matters for Pfizer, as around 12% of its total revenue comes from vaccine sales in the U.S. So far, the company's 2025 guidance does not factor in any potential changes to U.S. health policy.</li>
</ul>
</li>
<li>Pfizer has manufacturing facilities in Belgium, Germany, India, Ireland, Italy, Japan, and Singapore. Like many other companies, it hasn't commented yet on how possible <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">pharmaceutical tariffs</a> might affect its profit margins or earnings per share. Analysts will likely get the best chance to ask management about this during the first-quarter 2025 earnings call.
<ul>
<li>&#8220;Our belief is that most/all companies will likely not quantify any potential impact at the moment,&#8221; Anderson writes.</li>
</ul>
</li>
<li>After the recent setback with danuglipron, the company still has an oral GLP-1 drug in early development and a GIPR blocker <a href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" target="_blank" rel="noreferrer noopener">in Phase 2 trials</a>.
<ul>
<li>However, if Pfizer is serious about expanding in the obesity space, it will likely need to consider mergers, acquisitions, or other business deals to strengthen its position.</li>
</ul>
</li>
</ul>
Price Action: PFE stock is down 0.88% at $21.95 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44903362/american-express-solid-revenue-and-spending-trends-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">American Express&#8217; Solid Revenue, Spending Trends Drive Analyst Optimism</a></li>
</ul>
Photo: Shutterstock

Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline

New filings from the Federal Election Commission show that several major players in the cryptocurrency industry donated a combined total of over $12.27 million to President Donald Trump's <a href="https://www.benzinga.com/24/12/42382407/ripple-ceo-brad-garlinhouse-admits-204m-crypto-super-political-action-committee-wouldnt-exist-if-gary-gensler-hadnt-been-the-sec-chair">2025 inauguration fund</a>.
What Happened: These <a href="https://docquery.fec.gov/cgi-bin/forms/C00894162/1889684/f132">contributions</a> highlight a growing political alignment between the digital asset sector and the current U.S. administration, which has positioned itself as an advocate for Bitcoin and broader crypto adoption.
Ripple Labs (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) emerged as the largest donor among crypto-related entities, contributing $4.8 million. 
Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) followed with a $2 million donation. 
Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), the largest publicly traded crypto exchange in the United States, contributed $1 million, as did stablecoin issuer Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), blockchain platform Solana Labs (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) and Kraken's parent company Payward Inc.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44901448/5-catalysts-that-could-drive-bitcoin-higher-bernstein">5 Catalysts That Could Drive Bitcoin Higher: Bernstein</a>
Hayden Adams, the founder of Uniswap (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>), contributed $245,727.56 on Jan. 9.
His personal donation marked one of the largest individual contributions from within the crypto community. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) infrastructure firm Consensys donated $100,000 through its parent company. 
Yuga Labs, the company behind the Bored Ape Yacht Club NFT collection, also donated $100,000.
The wave of crypto-linked donations comes as the Trump administration pushes for deeper integration of digital assets into the U.S. financial system. 
Why It Matters: The president has pledged to make America a "Bitcoin superpower," and lawmakers are currently advancing bills aimed at creating a formal regulatory framework for stablecoins and other digital assets.
These contributions mark a stark contrast from the regulatory hostility the crypto industry faced in the years following the collapse of FTX and the shutdown of crypto-friendly banks like Silvergate and Signature. 
The shift in political posture appears to have reignited confidence among crypto firms, many of which are now seeking stronger ties with policymakers and government institutions.
The $12.27 million total from crypto firms represents one of the largest sector-specific fundraising blocs for the inauguration, placing the industry alongside energy, finance, and technology in political influence.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44898586/strategy-adds-555-million-in-bitcoin-ups-stash-to-538200-btc">Strategy Adds $555 Million In Bitcoin, Ups Stash To 538,200 BTC</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$UNI

$USDC

$XRP

COIN

HOOD

Ripple, Coinbase, Solana Among Crypto Firms Contributing Over $12M To Trump's Inauguration Fund

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is increasingly being compared to gold as investors examine macroeconomic dynamics and shifting <a href="https://www.benzinga.com/markets/forex/25/04/44893412/gold-rallies-to-record-dollar-drops-global-markets-today-while-us-slept">global monetary sentiment</a>.
What Happened: Prominent trader Unipcs on Monday <a href="https://x.com/theunipcs/status/1914196230042681638">pointed</a> out that gold recently hit a market capitalization of $22.785 trillion, up $7 trillion in just 10 months. 
Bitcoin sits at $1.7 trillion, representing just 7.46% of gold's market value and 24% of its recent gains. Bitcoin is &#8220;incredibly undervalued&#8221; and primed to catch up, according to the trader.
Financial commentator IncomeSharks highlighted that $7 trillion is currently parked in money market funds, with around $14 trillion expected to flow into risk assets like stocks and crypto over the next 10–20 years, largely through wealth transfers.
In an appearance on CNBC on Monday, Tom Lee, Head of Research at Fundstrat, <a href="https://www.youtube.com/watch?v=BF7ndR5TtAU">said</a> that institutional selling due to de-leveraging weighed on Bitcoin earlier this year. 
However, with that phase now over, Bitcoin is positioned to rise and catch up with gold as a non-dollar asset.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894280/how-traders-can-make-money-when-bitcoin-trades-sideways-10x-research">How Traders Can Make Money When Bitcoin Trades Sideways: 10x Research</a>
What's Next: In an X post on Monday, Bitcoin commentator Stack Hodler emphasized the need to stop measuring wealth in U.S. dollars, urging a shift toward Bitcoin, gold and Swiss francs as more accurate barometers of value.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The United States Dollar is collapsing. If you&#39;re an American, you need to begin pricing your assets in Bitcoin, gold, and Swiss Francs to see how they are actually performing. <a href="https://t.co/URnvuvlz7u">pic.twitter.com/URnvuvlz7u</a>
&mdash; Stack Hodler (@stackhodler) <a href="https://twitter.com/stackhodler/status/1914281907304440276?ref_src=twsrc%5Etfw">April 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a follow-up <a href="https://x.com/stackhodler/status/1914248395121713388">post</a>, he called Bitcoin and gold "hard money" without counter-party risk, dubbing this the &#8220;most important thesis of the decade.&#8221; 
He noted that the global monetary order is shifting, and while gold will benefit from its status and liquidity, Bitcoin will outperform in gains. 
Stack Hodler also credited Larry Fink's ETF timing as strategic, stating a major capital wave is on the way.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44896411/bitcoin-catapults-to-87000-what-is-going-on">Bitcoin Catapults To $87,000: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Bitcoin Spikes But Gold Surges: What's Driving The Underperformance?

Argus Research analyst David Toung downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Buy to Hold.

Downgrades

Argus Research Downgrades UnitedHealth Group to Hold

Jefferies analyst John Hecht maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Hold and lowers the price target from $14 to $12.

NAVI

Jefferies Maintains Hold on Navient, Lowers Price Target to $12

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Comments

4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) Opzioni

4D Molecular Therapeutics (NASDAQ:FDMT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO